Novimmune SA announced that it has closed a Series B financing round for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.
Dr. Jonathan Hepple, Partner at Rosetta, has joined Novimmune’s Board of Directors. Dr. Hepple brings more than 15 years’ investment experience in the life science industry. He is a co-founder of Rosetta Capital, an advisory and venture capital firm focused on the life sciences sector.